Alpha 2.0
Login Register
» Authors » J Flores-Montero

J Flores-Montero

Explore the profile of J Flores-Montero including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 992
Followers 0
Related Specialties
Hematology
Oncology
Top 10 Co-Authors
A Orfao
J J M van Dongen
V H J van der Velden
S Bottcher
L Sedek
T Szczepanski
T Kalina
P Lucio
A Mendonca
M B Vidriales
Published In
Leukemia
Best Pract Res Clin Haematol
Blood Cancer J
Affiliations
Soon will be listed here.
Recent Articles
1.
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
Sanoja-Flores L, Flores-Montero J, Garces J, Paiva B, Puig N, Garcia-Mateo A, et al.
Blood Cancer J . 2018 Nov; 8(12):117. PMID: 30455467
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma...
2.
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al.
Leukemia . 2017 Jan; 31(10):2094-2103. PMID: 28104919
Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM)...
3.
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
Kalina T, Flores-Montero J, van der Velden V, Martin-Ayuso M, Bottcher S, Ritgen M, et al.
Leukemia . 2012 Sep; 26(9):1986-2010. PMID: 22948490
The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8-color flow cytometry with fully standardized laboratory procedures and antibody...
4.
Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia
Dekking E, van der Velden V, Varro R, Wai H, Bottcher S, Kneba M, et al.
Leukemia . 2012 Sep; 26(9):1976-85. PMID: 22948489
The PML-RARA fusion protein is found in approximately 97% of patients with acute promyelocytic leukemia (APL). APL can be associated with life-threatening bleeding complications when undiagnosed and not treated expeditiously....
5.
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
van Dongen J, Lhermitte L, Bottcher S, Almeida J, van der Velden V, Flores-Montero J, et al.
Leukemia . 2012 May; 26(9):1908-75. PMID: 22552007
Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color antibody...
6.
Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay
Dekking E, van der Velden V, Bottcher S, Bruggemann M, Sonneveld E, Koning-Goedheer A, et al.
Best Pract Res Clin Haematol . 2010 Dec; 23(3):333-45. PMID: 21123134
Nowadays, the presence of specific genetic aberrations is progressively used for classification and treatment stratification, because acute leukemias with the same oncogenetic aberration generally form a clinically and diagnostically homogenous...
7.
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients
Weerkamp F, Dekking E, Ng Y, van der Velden V, Wai H, Bottcher S, et al.
Leukemia . 2009 Apr; 23(6):1106-17. PMID: 19387467
BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase domain, which can be blocked by specific inhibitors, thereby providing effective treatment. This makes detection of BCR-ABL aberrations of...